ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 353

Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets

Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: diagnosis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Psoriatic Arthritis (PsA) is a heterogeneous disease with widely varying clinical features and outcomes. Phenotypic heterogeneity may reflect genetic heterogeneity. We aimed to investigate whether the interval between the onset of psoriasis and PsA could be used to define more homogeneous subsets of PsA.

Methods:

Data on the age at onset of psoriasis and PsA, clinical and radiographic features at baseline as well as HLA B*27 and C*06 status was obtained from a large well-phenotyped PsA cohort. Patients were divided into 4 quartiles based on the time interval between the onset of psoriasis and the onset of PsA. The distribution of the above HLA alleles between the 4 quartiles was investigated. Subsequently, the patients were divided into 2 groups by combing the first two and the last two quartiles. Differences between the clinical and radiographic features at baseline (t-tests, chi-squared test, logistic regression) between the two groups were then investigated. 

Results:

1202 patients [56.7% males, mean (s.d.) age at first visit 47.4 (13.3) years, duration of psoriasis 18.2 (13.3) years, duration of PsA  10.1 (9.0) years] were distributed into the following 4 quartiles based on the time interval between onset of psoriasis and PsA- quartile 1: <0 years (n=318 patients, 26.5%), quartile 2: 0-5 years (n=291 patients, 24.2%), quartile 3: 5-13 years (n=262 patients, 21.8%) and quartile 4: >=13 years (n=331 patients, 27.5%). The distribution of HLA C*06 by quartile was 15.5%, 23.0%, 29.7% and 36.3% (trend test p-value <0.0001), while that of HLA B*27 was 21.2%, 18.1%, 15.6%, and 13.1% (trend test p-value =0.01), respectively.

At baseline, compared to group 1 (quartile 3 and 4), group 0 (quartile 1 and 2) had a significantly higher proportion of males, older age at onset of psoriasis but lower age at onset of PsA, lower PASI scores, higher prevalence of dactylitis, radiographic joint damage and patients treated with NSAIDs. There was no significant difference in the tender and swollen joint counts, ESR and the proportion of patients treated with DMARDs and biologics (Table 1). Since the proportion of patients positive for HLA B*27 and C*06 were different between the two groups, we examined whether the differences remained after adjusting for HLA status. After adjusting for HLA B*27 positivity there were no significant differences in the proportion of males, age at onset of PsA, and PASI score. When adjusting for HLA C*06 there was no difference in the proportion of males. When adjusting for HLA B*27 and C*06 differences between the two groups in age at onset of psoriasis, age at onset of PsA, PASI score, dactylitis and radiographic damage remained significant (p<0.05).

Conclusion:

There are differences in the clinical phenotype of PsA when taking the interval between the onset of psoriasis and PsA into account. These differences are not fully explained by the differences in the HLA -B*27 and –C*06 status between the two groups.

 

Table 1

 

Group 0 (N=609)

Group 1 (N=593)

P value

Age at first visit

43.38 (13.38)

44.57 (12.75)

0.1147

Males

370 (60.76%)

311 (52.45%)

0.0037

Age at psoriasis onset

35.01 (14.12)

21.92 (12.18)

<0.0001

Age at onset of PsA

35.38 (13.69)

38.93 (12.85)

<0.0001

Tender joint count

9.42 (9.10)

8.40 (8.20)

0.0664

Swollen joint count

5.08 (4.77)

5.18 (5.95)

0.7859

PASI

4.56 (6.86)

7.24 (9.17)

<0.0001

Dactylitis

217 (35.75%)

162 (27.41%)

0.0019

ESR

24.30 (19.83)

23.11 (21.31)

0.3464

Patients with erosions

296 (57.14%)

253 (48.28%)

0.0042

Modified Steinbrocker score

14.44 (34.37)

9.40 (26.45)

0.0082

Patients with at least unilateral sacroiliitis

182 (35.14%)

159 (30.34%)

0.0993

Patients satisfying NY criteria

137 (26.45%)

117 (22.33%)

0.1215

Treatment with NSAIDs

478 (82.84%)

423 (76.35%)

0.0067

Treatment with DMARDs

306 (53.31%)

269 (48.47%)

0.1038

Treatment with biologics

34 (6.19%)

38 (7.22%)

0.499

HLA B*27

93 (19.75%)

63 (14.16%)

0.0245

HLA C*06

90 (19.11%)

149 (33.56%)

<0.0001

*Mean (standard deviation) or proportion


Disclosure:

A. Thavaneswaran,
None;

V. Chandran,
None;

D. D. Gladman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-interval-between-the-onset-of-psoriasis-and-the-onset-of-psoriatic-arthritis-may-define-disease-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology